MedTrace Logo

Circadian Rhythm Disruption Effects on Smoke Inhalation

NCT04955431 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-05-30

Study results available
· View outcomes & findings →

Summary

Particulate matter exposure during smoke inhalation provokes inflammatory immune responses in people exposed to burning biomass including fire fighters and civilians. Persistent occupational exposure to particulate matter represents a unique hazard for firefighters, underpinning a burgeoning research area. This trial will evaluate the effects of sleep deprivation and circadian rhythm disruption on the inflammatory response to woodsmoke associated particulate matter exposure. Participants will undergo 2 experimental trials in a randomized cross-over design. Participants will have either an 8-hour sleep opportunity or a 4-hour sleep opportunity prior to reporting to lab for a 45 minute simulated firefighting trial (wood smoke associated particulate matter filtered to 2.5 um at a concentration of 250 ug/m\^3, while exercising at a moderate intensity). The effects of sleep restriction and simulated firefighting will be measured.

Conditions

  • Smoke Inhalation
  • Inflammation
  • Sleep Deprivation
  • Circadian Rhythm Sleep Disorder, Shift Work Type

Interventions

BEHAVIORAL

Sleep Restriction

Participants will be allowed \~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.

BEHAVIORAL

Normal Sleep

Participants will be allowed \~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.

Sponsors & Collaborators

  • University of Nevada, Las Vegas

    collaborator OTHER

  • University of Montana

    lead OTHER

Principal Investigators

  • John C Quindry, PhD · University of Montana

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-24
Primary Completion
2022-03-17
Completion
2022-04-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04955431 on ClinicalTrials.gov